BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2025 8:38:07 AM | Browse: 352 | Download: 96
 |
Received |
|
2025-05-28 09:57 |
|
Peer-Review Started |
|
2025-05-28 09:58 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-06-11 03:35 |
|
Revised |
|
2025-06-23 17:26 |
|
Second Decision |
|
2025-08-05 02:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-08-06 01:50 |
|
Articles in Press |
|
2025-08-06 01:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-08-20 09:55 |
|
Typeset the Manuscript |
|
2025-09-01 08:23 |
|
Publish the Manuscript Online |
|
2025-09-15 08:38 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhao Gao, Zheng-Fei Zhou, Xiao-Yan Wang, Tao Song, Shi-Kai Wu and Xuan Jin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital) |
No. 2022CR65 |
|
| Corresponding Author |
Xuan Jin, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. 27051079@qq.com |
| Key Words |
Microsatellite stable; Metastatic colorectal cancer; Immune checkpoint inhibitors; Programmed death 1 |
| Core Tip |
This study aims to evaluate the effectiveness of chemoimmunotherapy (CIT) as the first-line regimen for microsatellite stable metastatic colorectal cancer verses standard-of-care therapy (5-fluorouracil/leucovorin/oxaliplatin/bevacizumab) in the real world. The efficacy of CIT in microsatellite stable metastatic colorectal cancercould potentially surpass that of standard first-line chemotherapy protocols. Further research is needed to investigate specific clinical characteristics or biomarkers to identify patients who may derive benefit from CIT approaches. |
| Publish Date |
2025-09-15 08:38 |
| Citation |
<p>Gao Z, Zhou ZF, Wang XY, Song T, Wu SK, Jin X. Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis. <i>World J Gastrointest Oncol</i> 2025; 17(9): 109949</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i9/109949.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i9.109949 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
